SavedAdd your journal

Journals / Türkderm-Deri Hastalıkları ve Frengi Arşivi / 2005 / Cilt: 39 - Sayı: 4

The effects of topical propylthiouracyl in plaque type psoriasis: A prospective, double-blind, placebo-controlled study

Plak tipi psoriasiste topikal propiltiyourasil kullanımı: Prospektif, çift kör-plasebo kontrollü bir çalışma

Bülbül Emel BAŞKAN
Şükran TUNALI
Balaban Şaduman ADIM
Köran Serap KARADOĞAN
Çıkman Semra TOKER
Hayriye SARICAOĞLU
Pages
255–259
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Results: The clinical scores of both PTU and placebo plaques decreased significantly after the treatment (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background and Design: Propylthiouracil (PTU) decreases the synthesis of thyroid hormon as well as having immune modulatory and free radical scavenging effects.
📊
Key Findings & Data:This study was performed to determine the efficacy of topical PTU in psoriasis-Materials and Methods: Different plaques of 16 patients with plaque psoriasis were treated with -5°/o topical PTU and placebo, three times daily for 8 weeks in a setting of a double-blind and placebo controlled study.
💡
Conclusion & Impact:Results: The clinical scores of both PTU and placebo plaques decreased significantly after the treatment (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Background and Design: Propylthiouracil (PTU) decreases the synthesis of thyroid hormon as well as having immune modulatory and free radical scavenging effects. Oral PTU has been shown to be effective for the treatment of plaque psoriasis in several studies. This study was performed to determine the efficacy of topical PTU in psoriasis-Materials and Methods: Different plaques of 16 patients with plaque psoriasis were treated with -5°/o topical PTU and placebo, three times daily for 8 weeks in a setting of a double-blind and placebo controlled study. Response to therapy was evaluated by using clinical score, histopathologic score and epidermal thickness. Results: The clinical scores of both PTU and placebo plaques decreased significantly after the treatment (p

Özet

Propiltiyourasil, tiroid hormon sentezini azaltmasının yanısıra immun düzenleyici ve serbest radikal toplayıcı ajan olarak etki etmektedir. Daha önce bazı çalışmalarda oral olarak uygulanan propiltiyourasil'in psoriasis tedavisinde etkili olduğu gösterilmiştir. Biz de bu çalışmada propiltiyourasil'i topikal olarak kullanarak psoriasis tedavisindeki etkinliğini incelemeyi amaçladık. Plak tipi psoriasis tanısı konulan toplam 16 hastanın farklı plaklarına 8 hafta boyunca %5'lik topikal propiltiourasil (PTU) ve plasebo uygulandı. Çift kör plasebo kontrollü olarak yapılan çalışmada tedaviye yanıt; klinik skor, histopatolojik skor ve epidermal kalınlık ölçülerek değerlendirildi. PTU ve plasebo uygulanan plaklarda tedavi sonrasında klinik skordaki azalma anlamlı bulundu (p

🔖

Cite This Article

BAŞKAN, B. E., TUNALI, Ş., ADIM, B. Ş., KARADOĞAN, K. S., TOKER, Ç. S., SARICAOĞLU, H. (2022). The effects of topical propylthiouracyl in plaque type psoriasis: A prospective, double-blind, placebo-controlled study. Türkderm-Deri Hastalıkları ve Frengi Arşivi, Cilt: 39 - Sayı: 4, 255–259. https://ajindex.com/articles/622196

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Van de Kerkhof P CM: Psoriasis. Dermatology. Ed. Bolognia Jorizzo Rapini. Spain, Mosby, 125-51
  2. Christophers E, Mrowietz U: Psoriasis. Dermatology in General Medicine. Ed. Fredberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI, Fitzpatrick TB. 6th edition. New York, Mc Graw Hill, 407-36
  3. Aydemir EH: Psoriasis ve benzeri dermatozlar. Dermatoloji. Ed. Tüzün Y, Koto¤yan A, Aydemir EH, Baransü O
  4. Bask›. Istanbul, Nobel Tıp Kitabevleri, 315-32
  5. Kormeili T, Lowe NJ, Yamauchi PS: Psoriasis: immunopathogenesis and evolving immunomodulators and systemic therapies: U.S. experiences. Br J Dermatol 2004;151:3-15
  6. Elias AN: Anti-thyroid thioureylenes in the treatment of psoriasis. Medical hypotheses 2004; 62: 431-37 6. Elias AN, Dangaran K, Barr RJ, Rohan MK, Goodman MM: A controlled trial of propylthiouracil in the treatment of patients with psoriasis. J Am Acad Dermatol 1994; 31: 455-8
  7. Elias AN, Goodman MM, Liem WH, Barr RJ: Propylthiouracil in psoriasis: results of an open trial. J Am Acad Dermatol 1993; 29(1): 78-81
  8. Elias AN, Goodman MM, Rohan MK, Alpern K, Barr RJ: Methimazole in psoriasis: results of an open trial. Dermatology 1993;187(1):26-9
  9. Elias AN, Nanda VS, Pandian R: Serum TNF-α in psoriasis after treatment with propylthiouracil, an anti-thyroid thioureylene. BMC Dermatology 2004; 4:4
  10. Elias AN, Barr RJ, Rohan MK, Dangaran K: Effect of orally administered antithyroid thioureylenes on PCNA and P53 expression in psoriatic lesions. Int J Dermatol 1995; 34(4):280-3
  11. Elias AN, Nanda VS,Barr RJ: Effect of PTU on IL-12 and IL-10 in psoriasis. J Drugs Dermatol 2003;2(6):645-8
  12. Elias AN, Nanda VS, Barr RJ: CD1a expression in psoriatic skin following treatment with propylthiouracil antithyroid thioureylene. BMC Dermatology 2003;3:3
  13. Köse K, Utaş S, Yazıcı C, Akdaş A, Keleştimur F: Effect of propylthiouracil on adenosine deaminase activitiy and thyroid function in patients with psoriasis. Br J Dermatol 2001;144:1121-26
  14. Utaş S, Köse K, Yazıcı C, Akdaş A, Keleştimur F: Antioxidant activity of propylthiouracil in patients with psoriasis. Clinical Biochemistry 2002;35:241-46.